Pharmaceutical Company ‘Darnytsia’ has registered in Poland a medicinal product used in the complex treatment of acute and chronic heart failure, acute and chronic renal failure, nephrotic syndrome, liver diseases,…
Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account…